Wednesday, April 01, 2026

Who is Medicus Pharma? #newsout #biotechinvesting #healthcareinnovation #medicuspharma

Mar 31, 2026

Medicus Pharma (NASDAQ: MDCX) is advancing innovative therapies with promising Phase 2 results in basal cell carcinoma, where up to 3 out of 4 patients avoided surgery using its microneedle-based treatment platform. The technology offers a minimally invasive alternative to traditional procedures, with potential benefits including no scarring, lower cost, and improved patient experience.

See the full interview here: https://youtu.be/C80cY55NAJA

Recommended

What Medicus Pharma Does #newsout #healthcareinnovation #biotechinvesting #medicuspharma

What Medicus Pharma Does #newsout #healthcareinnovation #biotechinvesting #medicuspharma

8 hours ago
Medicus Pharma Reports Breakthrough Skin Cancer Results and Expands Oncology Pipeline

Medicus Pharma Reports Breakthrough Skin Cancer Results and Expands Oncology Pipeline

8 hours ago
Medicus Pharma Reports Strong Phase 2 Results for Skinject in Skin Cancer Treatment

Medicus Pharma Reports Strong Phase 2 Results for Skinject in Skin Cancer Treatment

1 day ago
Virtuix Signs U.S. Navy Deal to Expand VR Military Training and Simulation | VTIX

Virtuix Signs U.S. Navy Deal to Expand VR Military Training and Simulation | VTIX

2 days ago
ACME Markets Launches Blockchain Lending Platform on Canton Network for Tokenized Assets

ACME Markets Launches Blockchain Lending Platform on Canton Network for Tokenized Assets

4 days ago
Vivos Expands Insurance Coverage for Sleep Apnea Treatment, Targets Profitability

Vivos Expands Insurance Coverage for Sleep Apnea Treatment, Targets Profitability

5 days ago
Open Page